Avectas

Avectas is a private, platform technology company developing the Solupore® system, an integrated, consumable-based cell engineering platform designed to consolidate and automate cell therapy manufacturing. The technology promises to dramatically reduce facility costs and labor inputs while increasing throughput, addressing key economic and scalability barriers in the autologous cell therapy market. Led by an experienced team and guided by a world-class scientific advisory board, Avectas is positioning its platform as an enabling solution for therapy developers seeking to scale production and improve patient access.

Solupore®: An integrated, consumable-based cell engineering platform that consolidates activation, transduction, expansion, and harvest into a closed, automated workflow. It features a decoupled scale-out architecture using satellite rockers for parallel processing, aiming to reduce facility footprint, labor, and cost while increasing throughput for autologous cell therapy manufacturing.

Avectas competes in the growing market for cell therapy manufacturing technologies. Competitors range from large life science tools companies (e.g., Thermo Fisher, Miltenyi Biotec, Lonza) with integrated systems to startups offering alternative automation and closed-system solutions. Avectas differentiates with its specific claim of decoupled, parallel scale-out architecture aimed at unprecedented reductions in facility footprint and cost.